Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Safety and efficacy of NX-2127 in R/R CLL: a Phase I study

Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, outlines results from a Phase I dose-escalation and cohort-expansion trial evaluating the safety, tolerability, and preliminary efficacy of NX-2127, a Bruton’s tyrosine kinase (BTK)-targeted protein degrader, in adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and B-cell malignancies. Overall, clinical responses and benefit were observed in heavily pretreated patients with CLL who have poor prognostic factors, including those with BTK mutations resistant to covalent and non-covalent BTK inhibitors, BCL2 mutations and those who were previously treated with both BTK and BCL2 inhibitors. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Nurix: Consultancy, Research Funding; Takeda Oncology: Research Funding; Astra Zeneca: Consultancy, Research Funding; Bayer Oncology: Research Funding; Bristol-Meyers-Squibb: Consultancy, Research Funding; Cyclacel: Research Funding; MEI: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Genentech: Consultancy; Morphosys: Consultancy; Incyte: Consultancy; Beigene: Consultancy; GSK: Consultancy; Pharmacyclics: Consultancy.